Changes in Patient-Reported Outcome Measures With a Technology-Supported Behavioral Lifestyle Intervention Among Patients With Type 2 Diabetes: Pilot Randomized Controlled Clinical Trial.
Patient-Reported Outcome Measurement Information System
behavioral lifestyle interventions
patient-reported outcome measures
patient-reported outcomes
self-management
self-monitoring
type 2 diabetes
Journal
JMIR diabetes
ISSN: 2371-4379
Titre abrégé: JMIR Diabetes
Pays: Canada
ID NLM: 101719410
Informations de publication
Date de publication:
24 Jul 2020
24 Jul 2020
Historique:
received:
10
04
2020
accepted:
21
06
2020
revised:
31
05
2020
entrez:
25
7
2020
pubmed:
25
7
2020
medline:
25
7
2020
Statut:
epublish
Résumé
In the United States, more than one-third of the adult population is obese, and approximately 25.2% of those aged ≥65 years have type 2 diabetes (T2D), which is the seventh leading cause of death. It is important to measure patient-reported outcomes and monitor progress or challenges over time when managing T2D to understand patients' perception of health and quantify the impact of disease processes or intervention effects. The evaluation of patient-reported outcome measures (PROMs) is especially important among patients with multiple chronic conditions in which clinical measures do not provide a complete picture of health. This study examined the feasibility of collecting Patient-Reported Outcome Measurement Information System (PROMIS) measures, and preliminarily evaluated changes in PROMIS scores and compared the scores with standard scores of the general US population. The parent study is a pilot randomized controlled clinical trial testing three different modes (mobile health [mHealth], paper diary, and control) of self-monitoring in a behavioral lifestyle intervention among overweight or obese patients with T2D. Patients with comorbid overweight or obesity and a diagnosis of T2D for at least 6 months were recruited from a diabetes education program. Participants were randomized to the following three groups: mHealth, paper diary, and control (standard of care) groups. Paper diary and mHealth experimental groups received additional behavioral lifestyle intervention education sessions, as well as tools to self-monitor weight, physical activity, diet, and blood glucose. All participants completed PROMIS-57 and PROMIS-Global Health (GH) version 1.0 questionnaires during visits at baseline, 3 months, and 6 months. The PROMIS-57 includes the following seven domains: anxiety, depression, fatigue, pain interference, physical function, satisfaction with participation in social roles, and sleep disturbance. The PROMIS-GH is composed of the following two domains: global mental health and global physical health. A total of 26 patients (mHealth, 11; paper diary, 9; control, 6) were included in our analysis. The study sample was predominantly African American (68%) and female (57%), with a mean age of 54.7 years and a mean BMI of 37.5 kg/m Our pilot study provides evidence for the feasibility of using PROMIS questionnaires to record important components of T2D-related symptoms among overweight or obese individuals. The results from our study support the use of PROMIS questionnaires to provide clinicians and researchers with a benchmark for assessing the overall need for symptom management and determining the success or challenges of an intervention. ClinicalTrials.gov NCT02858648; https://clinicaltrials.gov/ct2/show/NCT02858648.
Sections du résumé
BACKGROUND
BACKGROUND
In the United States, more than one-third of the adult population is obese, and approximately 25.2% of those aged ≥65 years have type 2 diabetes (T2D), which is the seventh leading cause of death. It is important to measure patient-reported outcomes and monitor progress or challenges over time when managing T2D to understand patients' perception of health and quantify the impact of disease processes or intervention effects. The evaluation of patient-reported outcome measures (PROMs) is especially important among patients with multiple chronic conditions in which clinical measures do not provide a complete picture of health.
OBJECTIVE
OBJECTIVE
This study examined the feasibility of collecting Patient-Reported Outcome Measurement Information System (PROMIS) measures, and preliminarily evaluated changes in PROMIS scores and compared the scores with standard scores of the general US population. The parent study is a pilot randomized controlled clinical trial testing three different modes (mobile health [mHealth], paper diary, and control) of self-monitoring in a behavioral lifestyle intervention among overweight or obese patients with T2D.
METHODS
METHODS
Patients with comorbid overweight or obesity and a diagnosis of T2D for at least 6 months were recruited from a diabetes education program. Participants were randomized to the following three groups: mHealth, paper diary, and control (standard of care) groups. Paper diary and mHealth experimental groups received additional behavioral lifestyle intervention education sessions, as well as tools to self-monitor weight, physical activity, diet, and blood glucose. All participants completed PROMIS-57 and PROMIS-Global Health (GH) version 1.0 questionnaires during visits at baseline, 3 months, and 6 months. The PROMIS-57 includes the following seven domains: anxiety, depression, fatigue, pain interference, physical function, satisfaction with participation in social roles, and sleep disturbance. The PROMIS-GH is composed of the following two domains: global mental health and global physical health.
RESULTS
RESULTS
A total of 26 patients (mHealth, 11; paper diary, 9; control, 6) were included in our analysis. The study sample was predominantly African American (68%) and female (57%), with a mean age of 54.7 years and a mean BMI of 37.5 kg/m
CONCLUSIONS
CONCLUSIONS
Our pilot study provides evidence for the feasibility of using PROMIS questionnaires to record important components of T2D-related symptoms among overweight or obese individuals. The results from our study support the use of PROMIS questionnaires to provide clinicians and researchers with a benchmark for assessing the overall need for symptom management and determining the success or challenges of an intervention.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT02858648; https://clinicaltrials.gov/ct2/show/NCT02858648.
Identifiants
pubmed: 32706652
pii: v5i3e19268
doi: 10.2196/19268
pmc: PMC7414397
doi:
Banques de données
ClinicalTrials.gov
['NCT02858648']
Types de publication
Journal Article
Langues
eng
Pagination
e19268Subventions
Organisme : NIA NIH HHS
ID : P30 AG044271
Pays : United States
Organisme : NIDCR NIH HHS
ID : R21 DE030603
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR002647
Pays : United States
Informations de copyright
©Rozmin Jiwani, Jing Wang, Andrea Berndt, Padmavathy Ramaswamy, Nitha Mathew Joseph, Yan Du, Jisook Ko, Sara Espinoza. Originally published in JMIR Diabetes (http://diabetes.jmir.org), 24.07.2020.
Références
PLoS One. 2016 Nov 18;11(11):e0166718
pubmed: 27861583
J Clin Epidemiol. 2016 May;73:89-102
pubmed: 26952842
J Gen Intern Med. 2017 Jun;32(6):640-647
pubmed: 28160187
J Clin Epidemiol. 2010 Nov;63(11):1179-94
pubmed: 20685078
JMIR Mhealth Uhealth. 2017 May 23;5(5):e69
pubmed: 28536089
JMIR Mhealth Uhealth. 2018 Jan 15;6(1):e20
pubmed: 29334479
J Adv Nurs. 2018 Mar;74(3):689-697
pubmed: 29114911
J Med Internet Res. 2014 Apr 09;16(4):e104
pubmed: 24718852
J Ambul Care Manage. 2018 Oct/Dec;41(4):274-287
pubmed: 29923844
NCHS Data Brief. 2017 Oct;(288):1-8
pubmed: 29155689
BMJ Open. 2019 Jan 17;9(1):e024008
pubmed: 30782722
JMIR Mhealth Uhealth. 2018 Apr 10;6(4):e92
pubmed: 29636320
Patient. 2017 Feb;10(1):117-131
pubmed: 27599978